Investigation on the Bidirectional Cortical Neuroprosthetic System

Status Recruiting

Clinical Trial Summary

The Bidirectional Cortical Neuroprosthetic System (BiCNS) consists of NeuroPort Microelectrode Array Systems and NeuroPort Electrodes (Sputtered Iridium Oxide Film), Patient Pedestals, the NeuroPort BioPotential Signal Processing System, and the CereStim C96 Programmable Stimulator. The goals of this early feasibility study consist of safety and efficacy evaluations of this device.

Clinical Trial Description

This proposed early feasibility, investigator-initiated study is led by Dr. Pablo A. Celnik, M.D. at Johns Hopkins Medicine (JHM). The Bidirectional Cortical Neuroprosthetic System (BiCNS) consists of modified versions of 510(k) cleared NeuroPort Electrode Array Systems (Blackrock Microsystems, Inc., Salt Lake City, UT) as well as a neurostimulator module (CereStim R96) for long term neural recording and intracortical microstimulation (ICMS) of the brain. The BiCNS is termed bidirectional because it permits both the recording of information from the brain for controlling an end effector device, as well as enabling information regarding that end effector to be returned to the brain in the form of ICMS. "End effector" in this sense is used to mean a physical or virtual device designed to interact with its (physical or virtual) environment. Electrode arrays will be implanted in the brain in pairs, with a pair comprising a recording array and a stimulating array. A total of six NeuroPort arrays, consisting of three array pairs, will be implanted in each study participant. Each pair will consist of an array implanted in primary motor cortex (M1) for recording and an array implanted in primary sensory cortex (S1) for stimulation and/or recording; both arrays in each pair will be connected to a single percutaneous pedestal as an external interface. In each participant, two such array pairs will be implanted in the hand/arm area of M1 and S1 in the dominant brain hemisphere (e.g., the left hemisphere for a right-handed individual). A third pair will be implanted in the hand/arm area of M1 and S1 in non-dominant hemisphere (e.g. right hemisphere for a right handed-individual). The recording arrays implanted in M1 are the NeuroPort microelectrode arrays with platinum (Pt) tips (K070272), whereas the ICMS arrays implanted in S1 are NeuroPort microelectrode arrays with Sputtered Iridium-Oxide Film (SIROF) tips (K110010). The study has Investigational Device Exemption (IDE) approval from FDA to implant these devices for 52 weeks (plus/minus 2 weeks). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03161067
Study type	Interventional
Source	Johns Hopkins University
Contact	Pablo A Celnik, MD
Phone	4105022446
Email	pcelnik@jhmi.edu
Status	Recruiting
Phase	N/A
Start date	August 1, 2017
Completion date	September 30, 2027

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04736849` - Epidural and Dorsal Root Stimulation in Humans With Spinal Cord Injury	N/A
Not yet recruiting	`NCT06437548` - Epidural Stimulation for Upper Extremity Function	N/A
Terminated	`NCT03513783` - Elbow Extension Restoration Surgery in People With Tetraplegia: Evolution of the Muscular Co-activations of the Upper Limb During the Post-operative Rehabilitation	N/A
Recruiting	`NCT05432999` - Extracorporeal Shockwave Therapy for Spasticity in People With Spinal Cord Injury	N/A
Completed	`NCT03698136` - Electrical Stimulation in Denervated Muscles of the Upper Limbs	N/A
Recruiting	`NCT05553457` - MyHand-SCI: An Active Hand Orthosis for Spinal Cord Injury	N/A
Completed	`NCT04020770` - Influence of Upper Extremity Vibration on Spasticity and Function in Persons With Tetraplegia	N/A
Completed	`NCT04964635` - TETRAGRIP II - Usability Trial of an FES Orthosis for People With Tetraplegia.	N/A
Recruiting	`NCT06094205` - Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Speech-02)	N/A
Enrolling by invitation	`NCT02602639` - Functional Electrical Stimulation With Rowing as Exercise After Spinal Cord Injury	N/A
Completed	`NCT01467856` - Sleep Disordered Breathing	N/A
Completed	`NCT00385918` - Robotically Assisted Treadmill Training in Spinal Cord Injury (SCI)	N/A
Recruiting	`NCT05724173` - Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia	N/A
Completed	`NCT05555914` - Neural Stimulation for Hand Grasp in People With Tetraplegia	N/A
Completed	`NCT03975075` - Biofeedback Treatment of Anxiety Associated With Chronic Spinal Cord Injury	N/A
Recruiting	`NCT01474148` - A Neuroprosthesis for Seated Posture and Balance	N/A
Active, not recruiting	`NCT03811301` - [BrainConnexion] - Neurodevice Phase I Trial	N/A
Terminated	`NCT01498991` - Spinal Cord Injury Leg Rehabilitation	Phase 1/Phase 2
Completed	`NCT03237091` - Enhancing Corticospinal Excitability to Improve Functional Recovery	N/A
Recruiting	`NCT05665998` - Brain Controlled Spinal Cord Stimulation in Participants With Cervical Spinal Cord Injury for Upper Limb Rehabilitation	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Investigation on the Bidirectional Cortical Neuroprosthetic System — BiCNS

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms